Twenty-five health groups signed on to a letter to the Trump administration, urging that FDA be exempted from the requirement to submit proposed rules for review by Congress and the administration.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
